Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

By L. Gramantieri, M. Ferracin, F. Fornari, A. Veronese, S. Sabbioni, Chang-Gong Liu, George A. Calin, C. Giovannini, E. Ferrazzí, G. Grazi and 3 more. Cancer Research, 2007

842 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/edae5def2f8a4ee692aa4d4a15cace379f88aaa5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations (2008, background): “expressed in the liver, is essential for HCV replication (18) and it modulates cyclin G1 expression in HCC cell-line ( 19 ).”
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. (2011, background): “See also Table S1. some deregulated miRNAs in HCC but none of them was based on deep sequencing (Gramantieri et al., 2007, 2008, 2009; Braconi and Patel, 2008; Ji et al., 2009a, 2009b; Ladeiro et al., 2008; Varnholt et al., 2008; Wang et al., 2008, 2009a; Wong et al., 2008; Murakami et al., 2006;…”
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. (2008, methodology): “The relative quantity of each miRNA in BC tissues, normalized to U6 RNA and relative to the expression in NAT, was calculated using the equation RQ = 2 DDCT, where DDCT = (CTmiRNA CTU6 RNA)BC (CTmiRNA CTU6 RNA)NAT and CT is the threshold cycle to detect fluorescence (Gramantieri et al. 2007).”
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma (2008, methodology): “Real-time RT–PCR analysis of miR-221 Accurate quantitation of mature miR-221 was obtained using TaqMan MicroRNA Assays (hsa-miR-221, N/P: 4373077; Applied Biosystems, Foster City, CA, USA), as previously described (Gramantieri et al., 2007).”
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties (2009, positive): “Expression of miR-122 has been found to be repressed in HCC (Kutay et al., 2006; Murakami et al., 2006; Gramantieri et al., 2007; Braconi and Patel, 2008; Budhu et al., 2008; Girard et al., 2008; Ladeiro et al., Received 25 January 2009; revised 8 June 2009; accepted 18 June 2009; published online…”
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death (2008, background): “…cell death in human malignant cholangiocytes (let-7a) HMGA2, RAS, IGF2BP1, c-Myc, NF2 and LIN28Ba Akao et al. (2006); Boyerinas et al. (2008); Gramantieri et al. (2007); Guo et al. (2006); Hebert et al. (2007); Iorio et al. (2005); Johnson et al. (2005); Lee et al. (2006a); Lee and Dutta…”
MicroRNAs in development and disease. (2011, background): “Another miR-122 validated target that is significant in hepatoceullar carcinogenesis is cyclin G1 (212).”